

Japan-based Ono Pharma inks multi target R&D deal with UK's PrecisionLife

16 December 2022 | News

To target some of the most challenging common central nervous system diseases



UK-based PrecisionLife has entered into a multi-target discovery and validation partnership with Japan's Ono Pharmaceutical. The R&D collaboration will leverage PrecisionLife's combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono.

Under the agreement, PrecisionLife will apply its combinatorial analytics platform to patient datasets to find multiple new therapeutic targets for development by Ono. PrecisionLife will use its considerable drug discovery expertise to provide Ono with a clear rationale for selection of targets with genetic validation and mechanistic hypotheses, preclinical validation, and patient stratification biomarkers to optimise clinical development of the assets.

Ono will select targets from PrecisionLife's recommendations and acquire the worldwide rights to develop and commercialize a pharmaceutical product acting on the target.

This research collaboration exemplifies the precision medicine and drug discovery capabilities of PrecisionLife in complex chronic diseases that have high unmet medical needs. PrecisionLife has analysed over 40 high-value disease indications and maintains a deep portfolio of insights and patented discoveries in its DiseaseBank repository.